Metformin and Molecular Effects in Triple-Negative Breast Cancer

Metformin and Molecular Effects in Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is an aggressive subtype with limited targeted treatment options, prompting interest in repurposing existing drugs such as metformin. Liu and colleagues investigated the biological and molecular effects of metformin on TNBC cells to better understand its potential anti-cancer mechanisms.
In this preclinical study, TNBC cell lines were treated with metformin, and researchers assessed changes in cell proliferation, cell cycle progression, and molecular signaling pathways. The study focused on identifying how metformin influences cancer cell metabolism and growth-related signaling at a cellular level.
The findings showed that metformin inhibited cell proliferation and induced cell cycle arrest in TNBC cells. These effects were associated with alterations in key signaling pathways involved in cellular metabolism and growth regulation, including activation of AMP-activated protein kinase (AMPK) and downstream inhibition of pathways that promote tumor growth. The study also highlighted changes in gene expression patterns, suggesting that metformin induces a distinct molecular response in TNBC cells.
Although this research was conducted in vitro and cannot be directly translated to clinical outcomes, it provides important mechanistic insight into how metformin may exert anti-cancer effects. These findings support further investigation into metformin as a potential adjunctive therapy in triple-negative breast cancer, particularly in strategies targeting cancer metabolism.

Reference:

Liu B, Fan Z, Edgerton SM, Deng XS, Alimova IN, Lind SE, Thor AD. Metformin induces unique biological and molecular responses in triple negative breast cancer cells. Cell Cycle. 2009;8(13):2031–2040. doi:10.4161/cc.8.13.8814. PMID: 19440038.